Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?

The ongoing debate regarding a potential role for hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer represents an excellent example of the rarely publicly discussed fundamental clash between the requirements of evidence-based medicine and the roles of clinical innovation...

Descripción completa

Detalles Bibliográficos
Autor principal: Markman, Maurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Controversies in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861367/
https://www.ncbi.nlm.nih.gov/pubmed/27009940
http://dx.doi.org/10.1634/theoncologist.2015-0486
_version_ 1782431209130819584
author Markman, Maurie
author_facet Markman, Maurie
author_sort Markman, Maurie
collection PubMed
description The ongoing debate regarding a potential role for hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer represents an excellent example of the rarely publicly discussed fundamental clash between the requirements of evidence-based medicine and the roles of clinical innovation and optimization of care for the individual patient.
format Online
Article
Text
id pubmed-4861367
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-48613672016-05-16 Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here? Markman, Maurie Oncologist Controversies in Oncology The ongoing debate regarding a potential role for hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer represents an excellent example of the rarely publicly discussed fundamental clash between the requirements of evidence-based medicine and the roles of clinical innovation and optimization of care for the individual patient. AlphaMed Press 2016-05 2016-03-23 /pmc/articles/PMC4861367/ /pubmed/27009940 http://dx.doi.org/10.1634/theoncologist.2015-0486 Text en ©AlphaMed Press
spellingShingle Controversies in Oncology
Markman, Maurie
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title_full Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title_fullStr Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title_full_unstemmed Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title_short Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
title_sort hyperthermic intraperitoneal chemotherapy in ovarian cancer: where do we go from here?
topic Controversies in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861367/
https://www.ncbi.nlm.nih.gov/pubmed/27009940
http://dx.doi.org/10.1634/theoncologist.2015-0486
work_keys_str_mv AT markmanmaurie hyperthermicintraperitonealchemotherapyinovariancancerwheredowegofromhere

Ejemplares similares